Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (10-Sep-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹863 Cr
Expense Ratio
0.97%
ISIN
INF209KB1O25
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Jul 2019
About this fund
As of 10-Sep-24, it has a Net Asset Value (NAV) of ₹34.86, Assets Under Management (AUM) of 862.61 Crores, and an expense ratio of 0.97%.
- Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has given a CAGR return of 27.20% since inception.
- The fund's asset allocation comprises around 91.38% in equities, 0.00% in debts, and 8.62% in cash & cash equivalents.
- You can start investing in Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹1000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+56.11%
+53.32% (Cat Avg.)
3 Years
+19.13%
+18.25% (Cat Avg.)
5 Years
+27.37%
+28.77% (Cat Avg.)
Since Inception
+27.20%
— (Cat Avg.)
Portfolio Summaryas of 31st August 2024
| Equity | ₹788.22 Cr | 91.38% |
| Others | ₹74.4 Cr | 8.62% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹125.01 Cr | 14.49% |
| Cipla Ltd | Equity | ₹69.52 Cr | 8.06% |
| Torrent Pharmaceuticals Ltd | Equity | ₹67.85 Cr | 7.87% |
| Aurobindo Pharma Ltd | Equity | ₹53.56 Cr | 6.21% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹51.22 Cr | 5.94% |
| Ajanta Pharma Ltd | Equity | ₹41.94 Cr | 4.86% |
| Fortis Healthcare Ltd | Equity | ₹40.15 Cr | 4.65% |
| Lupin Ltd | Equity | ₹36.79 Cr | 4.26% |
| Reverse Repo | Cash - Repurchase Agreement | ₹36 Cr | 4.17% |
| Clearing Corporation Of India Limited | Cash - Repurchase Agreement | ₹35.81 Cr | 4.15% |
| Alkem Laboratories Ltd | Equity | ₹30.71 Cr | 3.56% |
| Alembic Pharmaceuticals Ltd | Equity | ₹25.45 Cr | 2.95% |
| Abbott India Ltd | Equity | ₹24.14 Cr | 2.80% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹24.02 Cr | 2.78% |
| Dr Reddy's Laboratories Ltd | Equity | ₹22.36 Cr | 2.59% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹20.17 Cr | 2.34% |
| Zydus Lifesciences Ltd | Equity | ₹18.02 Cr | 2.09% |
| Strides Pharma Science Ltd | Equity | ₹18.02 Cr | 2.09% |
| Gland Pharma Ltd | Equity | ₹17.95 Cr | 2.08% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹17.58 Cr | 2.04% |
| Star Health and Allied Insurance Co Ltd | Equity | ₹15.37 Cr | 1.78% |
| Emcure Pharmaceuticals Ltd | Equity | ₹12.56 Cr | 1.46% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹11.45 Cr | 1.33% |
| Mankind Pharma Ltd | Equity | ₹11.15 Cr | 1.29% |
| Sanofi Consumer He | Equity | ₹9.56 Cr | 1.11% |
| Medi Assist Healthcare Services Ltd | Equity | ₹8.47 Cr | 0.98% |
| Vinati Organics Ltd | Equity | ₹7.67 Cr | 0.89% |
| Sanofi India Ltd | Equity | ₹7.53 Cr | 0.87% |
| Net Receivables / (Payables) | Cash | ₹2.58 Cr | 0.30% |
Allocation By Market Cap (Equity)
Large Cap Stocks
40.24%
Mid Cap Stocks
32.30%
Small Cap Stocks
13.96%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹755.62 Cr | 87.60% |
| Financial Services | ₹15.37 Cr | 1.78% |
| Basic Materials | ₹7.67 Cr | 0.89% |
Risk & Performance Ratios
Standard Deviation
This fund
16.13%
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
0.80
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Fund Managers
Dhaval Shah
Since July 2019
Dhaval Joshi
Since November 2022
Additional Scheme Detailsas of 31st August 2024
ISIN | INF209KB1O25 | Expense Ratio | 0.97% | Exit Load | 1.00% | Fund Size | ₹863 Cr | Age | 11 Jul 2019 | Lumpsum Minimum | ₹1,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
- If units are sold after 1 year from the date of investment: Gains up to INR 1.25 lakh in a financial year are exempt from tax. Any gains exceeding INR 1.25 lakh are taxed at a rate of 12.5%.
- If units are sold within 1 year from the date of investment: The entire amount of gain is taxed at a rate of 20%.
- Holding the units: No tax is applicable as long as you continue to hold the units.
Dividend Taxation:
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹14.97 Cr | 55.4% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹862.61 Cr | 56.1% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹862.61 Cr | 53.9% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹37.00 Cr | 52.4% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹183.39 Cr | 56.3% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹183.39 Cr | 53.4% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2560.38 Cr | 52.6% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2560.38 Cr | 50.4% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 53.1% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.87 Cr | 51.3% |
About the AMC
Total AUM
₹3,85,953 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Other Funds by Aditya Birla SL Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth?
What are the returns of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth?
What is the portfolio composition of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth?
Who manages the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth?
- Dhaval Shah
- Dhaval Joshi
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.